Nasometin (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the nasal mucosa, altering gene transcription to suppress inflammatory cytokines, reduce leukocyte migration and decrease vascular permeability. This anti‑inflammatory action lessens swelling and irritation within the nasal passages.

The specific dosing regimen for Nasometin is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and the product label.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Nasometin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasometin (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with lower‑potency agents such as fluticasone, it may achieve symptom control with a smaller volume of spray, but the choice depends on individual response and physician preference.

Nasometin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme temperature fluctuations to maintain its stability and efficacy.

Nasometin is administered as a nasal spray. The patient gently inserts the nozzle into one nostril, closes the opposite nostril, and sprays the prescribed number of sprays while breathing in gently. The same procedure is repeated for the other nostril if directed by the prescriber.

Serious risks, though rare, include adrenal suppression, increased intra‑ocular pressure leading to glaucoma, cataract formation, severe nosebleeds and opportunistic infections such as nasal fungal growth. Patients should report any unusual symptoms promptly to their healthcare provider.

Nasometin should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, active nasal infections, or uncontrolled glaucoma. It is also contraindicated in patients for whom systemic corticosteroid exposure is contraindicated without prior medical evaluation.